Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890478 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3NPC1RAB9ATDP1 | |
| SCHEMBL19996590 | 0.78 | NR1H3 (0.51) | NR1H2NR1H3NPC1RAB9ASIGMAR1 | |
| SCHEMBL679761 | 0.76 | NR1H3 (0.68) | NR1H2NR1H3NPC1RAB9ASIGMAR1 | |
| SCHEMBL822566 | 0.75 | NR1H3 (1.00) | NR1H2NR1H3NPC1RAB9ASIGMAR1 | |
| SCHEMBL5924399 | 0.73 | NR1H2 (0.63) | NR1H2NR1H3NPC1RAB9ANUDT1 | |
| SCHEMBL27217204 | 0.73 | NR1H3 (0.63) | NR1H2NR1H3NPC1RAB9ASIGMAR1 | |
| SCHEMBL12340918 | 0.72 | NR1H2 (0.61) | NR1H2NR1H3NPC1RAB9ASIGMAR1 | |
| SCHEMBL12343973 | 0.70 | NR1H3 (0.59) | NR1H2NR1H3NPC1RAB9ASIGMAR1 | |
| SCHEMBL22307346 | 0.70 | NR1H3 (0.82) | NR1H2NR1H3NPC1RAB9AKDM4C | |
| SCHEMBL20489021 | 0.69 | SMN1; SMN2 (0.63) | NR1H2NR1H3NPC1RAB9ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | NR1H2 2806/4885NR1H3 2793/4885NPC1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.